BRIDGEWATER, N.J., Sept. 26, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension, a bioequivalent prescription generic version of Zegerid®1 Powder for Oral Suspension (20mg/1680mg and 40mg/1680mg), into the US market.
Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final ANDA approvals; 2 tentative approvals; and 10 ANDAs under review with the United States Food & Drug Administration.
About Ajanta Pharma
Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, pharmaceuticals across 30+ countries.
For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
1 Zegerid® is a registered trademark of Santarus Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-omeprazole-and-sodium-bicarbonate-powder-for-oral-suspension-300333658.html
SOURCE Ajanta Pharma USA Inc.